Armodafinil is the isolated R-enantiomer of the racemic wakefulness-promoting agent modafinil, marketed under the brand name Nuvigil. While chemically half of the same molecule, armodafinil represents a deliberate pharmacokinetic refinement — by removing the shorter-lived S-enantiomer, Cephalon created a drug that maintains higher plasma concentrations later in the day, translating to more sustained wakefulness without increasing the total dose .
Clinical Profile
Armodafinil is FDA-approved for three indications: excessive sleepiness associated with narcolepsy,obstructive sleep apnea/hypopnea syndrome (OSAHS) as adjunct to continuous positive airway pressure, andshift work sleep disorder (SWSD) . Standard dosing is 150-250 mg taken once daily in the morning (or one hour before the start of a work shift for SWSD). The drug is classified as a Schedule IV controlled substance in the United States, reflecting its lower abuse potential relative to traditional stimulants like amphetamine.
How It Differs from Modafinil
The critical distinction is pharmacokinetic, not pharmacodynamic. Both armodafinil and racemic modafinil share the same terminal elimination half-life of approximately 13 hours, but their plasma concentration curves diverge significantly . Racemic modafinil exhibits biphasic elimination because its S-enantiomer clears rapidly (half-life of 4-5 hours), causing an initial steep plasma decline. Armodafinil maintains a monophasic decline, producing area-under-the-curve (AUC) values 33-40% higher than an equivalent milligram dose of modafinil . In practical terms, this means armodafinil at 150 mg provides late-day wakefulness comparable to modafinil at 200 mg, with potentially fewer end-of-day rebound symptoms.
Subjective Experience
Users consistently describe armodafinil as "cleaner" and "smoother" than modafinil, with less of the jittery overstimulation that some people experience with the racemic mixture. The subjective effects — enhanced focus, reduced fatigue, improved verbal fluency — are qualitatively identical to modafinil, but the temporal profile differs. Many users report that armodafinil's effects feel more evenly distributed across the day, whereas modafinil can produce a noticeable peak-and-trough pattern .
References
Darwish M, Kirby M, Hellriegel ET, Robertson P Jr. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives. Clinical Drug Investigation. 2009;29(9):613-623. FDA. Nuvigil (armodafinil) Prescribing Information. NDA 021875. Approved June 2007. Harsh JR et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Current Medical Research and Opinion. 2006;22(4):761-774.
Safety at a Glance
High Risk- Hormonal birth control - Modafinil reduces the effectiveness of hormonal birth control for
- Toxicity: The long-term safety and effectiveness of armodafinil has not been determined. Anecdotal evidence suggests a lack of ...
- Dangerous with: 25x-NBOH, 25x-NBOMe, Atropa belladonna, Datura, MDMA (+3 more)
- Overdose risk: LD50) from either armodafinil or modafinil for human beings has never been reached . No life-thre...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 8 hrs – 15 hrsHow It Feels
Armodafinil does not arrive as a wave. It arrives as a quiet, relentless clarification. Within one to two hours of oral ingestion, the fog of fatigue begins to lift. It does not happen all at once. Instead, there is a gradual realization that the heaviness behind the eyes has dissipated, that the desire to close them and drift has been replaced by a calm willingness to remain engaged with whatever task is at hand. The alertness feels natural, as though you have simply slept well rather than taken a pharmaceutical. This is the defining quality of armodafinil's onset: it does not feel like stimulation. It feels like the absence of tiredness.
At its peak, which can persist for six to twelve hours depending on individual metabolism, armodafinil produces a state of sustained, effortless wakefulness. The mind is clear, attentive, and capable of prolonged focus. There is no jitteriness, no racing thoughts, no euphoria. Instead, there is a patient, unflagging alertness that makes it possible to work through tasks that would normally require breaks or sustained effort to maintain concentration. Executive function improves: planning feels easier, prioritization becomes more natural, and the gap between recognizing what needs to be done and actually doing it narrows appreciably.
The physical experience is remarkably spare. Heart rate may increase very slightly. Appetite is mildly suppressed, often noticed only retrospectively when one realizes it has been seven hours since eating without any hunger signals. There may be a subtle dryness of the mouth and, occasionally, a faint headache that responds to hydration. The body feels normal, functional, and unperturbed. There is none of the peripheral nervous system overdrive that characterizes traditional stimulants: no sweating, no vasoconstriction, no tremor, no jaw clenching.
The offset of armodafinil is as gradual as its onset. Late in the day, the sustained wakefulness begins to soften, and the ordinary rhythms of fatigue begin to reassert themselves. Sleep, if the dose was taken in the morning, is usually achievable by the normal bedtime, though the quality of sleep may be slightly reduced. Some users report a subtle emotional flatness during the active period, a sense that while cognition is enhanced, the richness of emotional experience has been marginally compressed. The following morning is typically clear, though those who have slept poorly may carry a mild deficit forward. The overall experience is one of quiet, efficient utility, a substance that does its job so unobtrusively that you may occasionally forget you have taken anything at all.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(10)
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Cognitive & Perceptual Effects
Cognitive(10)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
- Motivation enhancement— A heightened sense of drive, ambition, and willingness to accomplish tasks, making productive effort...
- Panic attack— A panic attack is a discrete episode of acute, overwhelming fear or terror that arises suddenly and ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Sleepiness— A progressive onset of drowsiness, heaviness, and the desire to sleep that pulls the individual towa...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Pharmacology
Dopamine Transporter Inhibition
Like modafinil, armodafinil's primary mechanism of action involves binding to the dopamine transporter (DAT) and inhibiting dopamine reuptake, leading to elevated extracellular dopamine concentrations in wake-promoting brain regions . Critically, the R-enantiomer binds to DAT with approximatelythreefold higher affinity than the S-enantiomer, making armodafinil the more pharmacologically potent half of the racemic mixture . PET imaging studies in humans confirm that both modafinil and armodafinil occupy DAT in the striatum at clinically relevant doses, producing 50-60% transporter occupancy — comparable to methylphenidate but substantially below cocaine-level occupancy .
Enantioselective Pharmacokinetics
The R-enantiomer of modafinil has an elimination half-life of approximately 15 hours, compared to only 4-5 hours for the S-enantiomer . This dramatic enantioselective difference explains why racemic modafinil shows biphasic plasma elimination — the S-enantiomer clears rapidly during the first phase, leaving the R-enantiomer to dominate the terminal phase. By isolating the R-enantiomer, armodafinil produces a monophasic elimination profile with plasma concentrations that remain significantly higher during the later portion of the dosing interval . After single-dose administration, armodafinil achieves AUC values 33-40% greater than equimolar doses of racemic modafinil, despite similar peak concentrations (Cmax) and time to peak (Tmax) .
Beyond DAT: Additional Mechanisms
While DAT inhibition is the best-characterized mechanism, the full pharmacological profile of armodafinil involves several additional systems. Modafinil and its enantiomers modulate orexin/hypocretin neurotransmission, activating wake-promoting neurons in the lateral hypothalamus through indirect mechanisms that remain incompletely understood . There is evidence for effects onGABAergic signaling (reduced GABA release in the cortex and sleep-promoting regions),histaminergic activation (increased histamine release in the tuberomammillary nucleus), andnoradrenergic enhancement (elevated norepinephrine in the prefrontal cortex) . The net effect is a coordinated enhancement of multiple arousal-promoting circuits without the monoamine flood that characterizes amphetamine-type stimulants.
Metabolism and Drug Interactions
Armodafinil is extensively metabolized in the liver, primarily by CYP3A4 with contributions fromCYP2C9 andCYP2C19 . Importantly, armodafinil acts as a moderate inducer of CYP3A4 and an inhibitor of CYP2C19, creating clinically significant drug interactions. It reduces the efficacy of hormonal contraceptives (ethinyl estradiol) through CYP3A4 induction, and can increase plasma levels of drugs metabolized by CYP2C19, including omeprazole and some antidepressants . The R-enantiomer has a longer half-life partly because it is metabolized more slowly than the S-enantiomer by hepatic enzymes.
Abuse Potential Assessment
Despite its dopaminergic mechanism, armodafinil exhibits relatively low abuse potential. The reinforcing effects are substantially weaker than those of amphetamine or methylphenidate at clinically relevant doses, likely because the rate of DAT occupancy increase is slower — a pharmacokinetic property strongly correlated with abuse liability . Self-administration studies in primates confirm that modafinil produces less reinforcement than cocaine or amphetamine, consistent with its Schedule IV classification .
References
Loland CJ et al. R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biological Psychiatry. 2012;72(5):405-413. Volkow ND et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain. JAMA. 2009;301(11):1148-1154. Darwish M et al. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives. Clinical Drug Investigation. 2009;29(9):613-623. Scammell TE, Saper CB. Orexin, drugs and motivated behaviors. Nature Neuroscience. 2005;8(10):1286-1288. FDA. Nuvigil (armodafinil) Prescribing Information. Clinical Pharmacology section. NDA 021875.
Detection Methods
Standard Drug Panel Inclusion
Armodafinil is the R-enantiomer of modafinil and, like modafinil, is not detected on standard immunoassay drug screens. It shares the same lack of structural similarity to amphetamines and produces no cross-reactivity on any standard drug panel. Armodafinil is Schedule IV in the United States and is not targeted by routine drug testing.
Urine Detection
Armodafinil and its metabolites (primarily modafinil acid) are detectable in urine for approximately 2 to 4 days. Because armodafinil is a single enantiomer, its metabolite profile is identical to the R-enantiomer fraction of racemic modafinil. Standard immunoassays do not detect armodafinil. Chiral LC-MS/MS analysis can determine enantiomeric composition but cannot distinguish armodafinil from modafinil use unless the timing of the sample is precisely known.
Blood and Saliva Detection
Armodafinil has a longer effective half-life than racemic modafinil (approximately 15 hours) and is detectable in blood for approximately 24 to 48 hours. Anti-doping testing by WADA-accredited laboratories includes armodafinil as a prohibited substance.
Hair Follicle Detection
Hair testing for armodafinil requires specialized methods identical to those for modafinil. Standard commercial panels do not include either compound.
Confirmatory Testing
LC-MS/MS with chiral separation can identify armodafinil and distinguish it from racemic modafinil based on enantiomeric ratio. Standard achiral LC-MS/MS cannot distinguish the two. WADA methods are available for anti-doping applications.
Reagent Testing
Like modafinil, armodafinil does not produce characteristic reactions with standard reagent kits. Pharmaceutical tablets have distinctive markings for visual identification. Reagent testing is not informative for this compound.
Interactions
| Substance | Status | Note |
|---|---|---|
| 25x-NBOH | Dangerous | — |
| 25x-NBOMe | Dangerous | — |
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| MDMA | Unsafe | — |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 25E-NBOH | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-2 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-21 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Alcohol | Uncertain | — |
| Dissociatives | Uncertain | — |
History
Development and Patent Strategy
Armodafinil was developed by Cephalon, Inc., a Pennsylvania-based pharmaceutical company that also manufactured the original racemic modafinil (Provigil). The development of armodafinil was widely recognized as apatent lifecycle management strategy — Provigil's core patents were approaching expiration, and isolating the R-enantiomer provided a chemically distinct product that could be separately patented and marketed while offering a genuine pharmacokinetic improvement .
FDA Approval
The FDA approved armodafinil (brand name Nuvigil) onJune 15, 2007, for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder — the same three indications as Provigil . Cephalon filed a supplemental New Drug Application seeking approval for jet lag disorder, but the FDA declined to approve this indication in 2010, citing insufficient evidence of clinical benefit.
Corporate Acquisitions and Generic Competition
In October 2011, Teva Pharmaceutical Industries completed its acquisition of Cephalon for approximately $6.8 billion, gaining control of both the Provigil and Nuvigil franchises . The acquisition was approved by the FTC on the condition that Cephalon grant generic modafinil rights to Par Pharmaceutical. Generic armodafinil became available in the United States inJune 2016 after the expiration of Nuvigil's core patents, with multiple manufacturers including Mylan, Teva, and Aurobindo receiving ANDA approvals . The entry of generics significantly reduced the price of armodafinil, making it more accessible as a first-line wakefulness-promoting agent.
References
Cephalon Inc. SEC Filing: Form 10-K Annual Report. 2007. FDA. NDA Approval Letter: Nuvigil (armodafinil) NDA 021875. June 15, 2007. Teva Pharmaceutical Industries. Press Release: Completion of Cephalon Acquisition. October 2011. Drugs.com. Generic Nuvigil Availability. FDA ANDA approvals database.
Harm Reduction
LD50) from either armodafinil or modafinil for human beings has never been reached]]. No life-threatening effects have taken place in clinical trials involving the administration of 1000mg to 1600mg of modafinil per day for 7 to 21 consecutive days. Intentional acute overdoses of 4500mg and 4000mg in two adult subjects and an accidental ingestion of 800mg by a three-year-old child did not result in any life-threatening effects or death. After overdosing on 5000mg of modafinil in a suicide attempt, a fifteen-year-old female reported a severe headache, nausea, and tachycardia, but did not appear to have any lethal or long-term effects.
Armodafinil, like racemic modafinil, may also possess addiction reinforcing properties, as evidenced by its self-administration in monkeys previously trained to administer cocaine; armodafinil was also partially discriminated as stimulant-like.mildly addictive with a low potential for abuse. It does not seem to be capable of causing psychological dependence among certain users.develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption). Armodafinil may present a cross-tolerance with Cross-all benzhydryl nootropics, meaning that after the consumption of armodafinil, certain nootropics such as modafinil and adrafanil may have a reduced effect. -Hormonal birth control** - Modafinil reduces the effectiveness of hormonal birth control for
Toxicity & Safety
The long-term safety and effectiveness of armodafinil has not been determined.
Anecdotal evidence suggests a lack of adverse health effects when sparingly used at small to moderate doses, although this must not be assumed. This compound is a commonly prescribed prescription medication, thus is considerably less likely to have adverse health effects than that of a typical research chemical.
It is strongly recommended that one use harm reduction practices when using this substance.
Lethal dosage
The median lethal dose at which 50% of participants die (LD50) from either armodafinil or modafinil for human beings has never been reached. No life-threatening effects have taken place in clinical trials involving the administration of 1000mg to 1600mg of modafinil per day for 7 to 21 consecutive days. Intentional acute overdoses of 4500mg and 4000mg in two adult subjects and an accidental ingestion of 800mg by a three-year-old child did not result in any life-threatening effects or death. After overdosing on 5000mg of modafinil in a suicide attempt, a fifteen-year-old female reported a severe headache, nausea, and tachycardia, but did not appear to have any lethal or long-term effects.
Tolerance and addiction potential
Armodafinil, like racemic modafinil, may also possess addiction reinforcing properties, as evidenced by its self-administration in monkeys previously trained to administer cocaine; armodafinil was also partially discriminated as stimulant-like. The chronic use of armodafinil can be considered as mildly addictive with a low potential for abuse. It does not seem to be capable of causing psychological dependence among certain users.
Tolerance to many of the effects of armodafinil develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). Armodafinil may present a cross-tolerance with all benzhydryl nootropics, meaning that after the consumption of armodafinil, certain nootropics such as modafinil and adrafanil may have a reduced effect.
Dangerous interactions
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
25x-NBOMe & 25x-NBOH - 25x compounds are highly stimulating and physically straining. Combinations with Armodafinil should be strictly avoided due to the risk of excessive stimulation and heart strain. This can result in increased blood pressure, vasoconstriction, panic attacks, thought loops, seizures, and heart failure in extreme cases.
Alcohol - Combining alcohol with stimulants can be dangerous due to the risk of accidental over-intoxication. Stimulants mask alcohol's depressant effects, which is what most people use to assess their degree of intoxication. Once the stimulant wears off, the depressant effects will be left unopposed, which can result in blackouts and severe respiratory depression. If mixing, the user should strictly limit themselves to only drinking a certain amount of alcohol per hour.
DXM - Combinations with DXM should be avoided due to its inhibiting effects on serotonin and norepinephrine reuptake. There is an increased risk of panic attacks and hypertensive crisis, or serotonin syndrome with serotonin releasers (MDMA, methylone, mephedrone, etc.). Monitor blood pressure carefully and avoid strenuous physical activity.
MDMA - Any neurotoxic effects of MDMA are likely to be increased when other stimulants are present. There is also a risk of excessive blood pressure and heart strain (cardiotoxicity).
MXE - Some reports suggest combinations with MXE may dangerously increase blood pressure and increase the risk of mania and psychosis.
Dissociatives - Both classes carry a risk of delusions, mania and psychosis, and these risk may be multiplied when combined.
Stimulants - Armodafinil may be dangerous to combine with other stimulants like cocaine as they can increase one's heart rate and blood pressure to dangerous levels.
Tramadol - Tramadol is known to lower the seizure threshold and combinations with stimulants may further increase this risk.
MAOIs - This combination may increase the amount of neurotransmitters such as dopamine to dangerous or even fatal levels. Examples include syrian rue, banisteriopsis caapi, and some antidepressants.
Hormonal birth control - Modafinil reduces the effectiveness of hormonal birth control for up to a month after use by increasing the activity of the enzyme CYP3A4/5. Notably, the same enzyme is inhibited by grapefruit juice.
Addiction Potential
mildly addictive with a low potential for abuse
Overdose Information
LD50) from either armodafinil or modafinil for human beings has never been reached]]. No life-threatening effects have taken place in clinical trials involving the administration of 1000mg to 1600mg of modafinil per day for 7 to 21 consecutive days. Intentional acute overdoses of 4500mg and 4000mg in two adult subjects and an accidental ingestion of 800mg by a three-year-old child did not result in any life-threatening effects or death. After overdosing on 5000mg of modafinil in a suicide attempt, a fifteen-year-old female reported a severe headache, nausea, and tachycardia, but did not appear to have any lethal or long-term effects.
Armodafinil, like racemic modafinil, may also possess addiction reinforcing properties, as evidenced by its self-administration in monkeys previously trained to administer cocaine; armodafinil was also partially discriminated as stimulant-like.mildly addictive with a low potential for abuse. It does not seem to be capable of causing psychological dependence among certain users.develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption). Armodafinil may present a cross-tolerance with Cross-all benzhydryl nootropics, meaning that after the consumption of armodafinil, certain nootropics such as modafinil and adrafanil may have a reduced effect. -Hormonal birth control** - Modafinil reduces the effectiveness of hormonal birth control for up to a month after use by increasing the activity of the enzyme CYP3A4/5. Notably, th
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Armodafinil is legally approved for medical purposes worldwide. However, it is illegal to sell and possess without a prescription in most countries.
Canada:** Modafinil is listed as a Schedule F prescription drug in Canada and it can be prescribed for human and veterinary use.
Germany:** Modafinil is a prescription medicine, according to Anlage 1 AMVV.
United Kingdom:** Armodafinil is not a licensed medicine in the United Kingdom and is not covered by the Misuse of Drugs Act 1971 so it may be considered illegal to produce, supply, or import under the Psychoactive Substances Act. However, it may not be covered by the Psychoactive Substances Act as it is a licensed medicine in many other countries and modafinil, the non-enantiopure substance that is comprised of armodafinil and the S-enantiomer of modafinil in equal proportions, is a licensed prescription-only medicine (POM) in the United Kingdom. In this case it would not be considered a criminal offence to possess this substance without a valid prescription and it could be legally be obtained with a valid prescription or through legal import of the substance for personal use as outlined in Section 13 of the Medicines Act 1968.
United States:** Armodafinil is a Schedule IV controlled substance in the United States. It is illegal to buy, sell, or possess the drug without a prescription or DEA license.
Responsible use
Nootropics
Stimulants
Modafinil
Armodafinil (Wikipedia)
Armodafinil (Isomer Design)
Armodafinil (DrugBank)
Darwish, M., Kirby, M., D’Andrea, D. M., Yang, R., Hellriegel, E. T., & Robertson, P. (2010). Pharmacokinetics of armodafinil and modafinil after single and multiple doses in patients with excessive sleepiness associated with treated obstructive sleep apnea: A randomized, open-label, crossover study. Clinical Therapeutics, 32(12), 2074–2087. https://doi.org/10.1016/j.clinthera.2010.11.009
Fuller, P., Vetrivelan, R., & Saper, C. (2014). Armodafinil-induced wakefulness in animals with ventrolateral preoptic lesions. Nature and Science of Sleep, 6, 57. https://doi.org/10.2147/NSS.S53132
Greve, D. N., Duntley, S. P., Larson-Prior, L., Krystal, A. D., Diaz, M. T., Drummond, S. P. A., … Thomas, R. J. (2014). Effect of Armodafinil on Cortical Activity and Working Memory in Patients with Residual Excessive Sleepiness Associated with CPAP-Treated OSA: A Multicenter fMRI Study. Journal of Clinical Sleep Medicine, 10(2), 143–153. https://doi.org/10.5664/jcsm.3440
Loland, C. J., Mereu, M., Okunola, O. M., Cao, J., Prisinzano, T. E., Mazier, S., … Newman, A. H. (2012). R-modafinil (armodafinil): A unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biological Psychiatry, 72(5), 405–413. https://doi.org/10.1016/j.biopsych.2012.03.022
Niemegeers, P., Maudens, K. E., Morrens, M., Patteet, L., Joos, L., Neels, H., & Sabbe, B. G. (2012). Pharmacokinetic evaluation of armodafinil for the treatment of bipolar depression. Expert Opinion on Drug Metabolism & Toxicology, 8(9), 1189–1197. https://doi.org/10.1517/17425255.2012.708338
Ramachandra, B. (2016). A Critical Review of Properties of Modafinil and Analytical, Bioanalytical Methods for its Determination. Critical Reviews in Analytical Chemistry, 46(6), 482–489. https://doi.org/10.1080/10408347.2016.1153948
T., M., M., M., N., S., & S., N. (2016). The pathogenesis of narcolepsy, current treatments, and prospective therapeutic targets. Expert Opinion on Orphan Drugs, 4(1), 63–82. https://doi.org/10.1517/21678707.2016.1117973
Tips (7)
Purchase Armodafinil from reputable vendors who provide third-party certificates of analysis (COA). Nootropic quality varies enormously between suppliers, and contamination or mislabeling is common in unregulated markets.
Start with a low dose of Armodafinil and increase gradually over days or weeks. Most nootropics have subtle effects that are best assessed after consistent use rather than from a single large dose.
Monitor your heart rate and blood pressure when using Armodafinil. Sustained elevated cardiovascular stress causes cumulative damage. If you experience chest pain, irregular heartbeat, or numbness in extremities, seek medical attention.
Armodafinil (like modafinil) induces CYP3A4 liver enzymes, which can reduce the effectiveness of hormonal contraceptives including birth control pills, patches, and rings. If you rely on hormonal birth control, use an additional barrier method while taking armodafinil and for one month after discontinuation. This interaction is listed in the prescribing information but often overlooked.
Armodafinil has a longer effective half-life than modafinil (the R-enantiomer persists longer). Take it early in the morning, ideally before 9am. Even a single dose can disrupt sleep if taken past noon. The standard dose is 150mg, and many people find that splitting to 75mg provides adequate wakefulness with fewer side effects like anxiety or headaches.
Armodafinil pairs well with a basic nootropic stack. Users report good synergy with racetams for cognitive enhancement. Stay well hydrated as it has mild diuretic effects. Headaches are the most common side effect and often respond to adequate water intake and adding a choline source to your stack.
Community Discussions (1)
See Also
References (4)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- PubChem: Armodafinil
PubChem compound page for Armodafinil (CID: 9690109)
pubchem - Armodafinil - TripSit Factsheet
TripSit factsheet for Armodafinil
tripsit - Armodafinil - Wikipedia
Wikipedia article on Armodafinil
wikipedia